| Year |
Citation |
Score |
| 2019 |
Low JY, Sirajuddin P, Moubarek M, Agarwal S, Rege A, Guner G, Liu H, Yang Z, De Marzo AM, Bieberich C, Laiho M. Effective targeting of RNA polymerase I in treatment-resistant prostate cancer. The Prostate. PMID 31524299 DOI: 10.1002/Pros.23909 |
0.604 |
|
| 2017 |
Guner G, Sirajuddin P, Zheng Q, Bai B, Brodie A, Liu H, Af Hallstrom T, Kulac I, Laiho M, De Marzo AM. Novel Assay to Detect RNA Polymerase I Activity in vivo. Molecular Cancer Research : McR. PMID 28119429 DOI: 10.1158/1541-7786.Mcr-16-0246 |
0.486 |
|
| 2016 |
Guner G, Sirajuddin P, Zheng Q, Liu H, Kulac I, Laiho MK, Marzo AMD. Abstract LB-186: Development and validation of a novel RNA in situ hybridization assay to detect RNA polymerase I activity in vivo Cancer Research. 76. DOI: 10.1158/1538-7445.Am2016-Lb-186 |
0.532 |
|
| 2014 |
Ringer L, Sirajuddin P, Tricoli L, Waye S, Choudhry MU, Parasido E, Sivakumar A, Heckler M, Naeem A, Abdelgawad I, Liu X, Feldman AS, Lee RJ, Wu CL, Yenugonda V, et al. The induction of the p53 tumor suppressor protein bridges the apoptotic and autophagic signaling pathways to regulate cell death in prostate cancer cells. Oncotarget. 5: 10678-91. PMID 25296977 DOI: 10.18632/Oncotarget.2528 |
0.753 |
|
| 2014 |
Peltonen K, Colis L, Liu H, Jäämaa S, Zhang Z, Af Hällström T, Moore HM, Sirajuddin P, Laiho M. Small molecule BMH-compounds that inhibit RNA polymerase I and cause nucleolar stress. Molecular Cancer Therapeutics. 13: 2537-46. PMID 25277384 DOI: 10.1158/1535-7163.Mct-14-0256 |
0.491 |
|
| 2014 |
Colis L, Ernst G, Sanders S, Liu H, Sirajuddin P, Peltonen K, DePasquale M, Barrow JC, Laiho M. Design, synthesis, and structure-activity relationships of pyridoquinazolinecarboxamides as RNA polymerase I inhibitors. Journal of Medicinal Chemistry. 57: 4950-61. PMID 24847734 DOI: 10.1021/Jm5004842 |
0.436 |
|
| 2012 |
Sirajuddin P, Das S, Ringer L, Rodriguez OC, Sivakumar A, Lee YC, Üren A, Fricke ST, Rood B, Ozcan A, Wang SS, Karam S, Yenugonda V, Salinas P, Petricoin E, et al. Quantifying the CDK inhibitor VMY-1-103's activity and tissue levels in an in vivo tumor model by LC-MS/MS and by MRI. Cell Cycle (Georgetown, Tex.). 11: 3801-9. PMID 22983062 DOI: 10.4161/Cc.21988 |
0.697 |
|
| 2012 |
Sirajuddin P, Das S, Ringer L, Salinas P, Rodriguez O, Moasser B, Yenugonda VM, Albanese C, Brown M. Abstract 4774: LC-MS/MS detection of the dansyl-modified biologically active CDK inhibitor VMY-1-103 using an in vivo model system Cancer Research. 72: 4774-4774. DOI: 10.1158/1538-7445.Am2012-4774 |
0.672 |
|
| 2012 |
Ringer L, Sirajuddin P, Yenugonda VM, Brown M, Rodriguez O, Albanese C. Abstract 3052: Role of p53 in cdk inhibitor VMY-1-103-induced apoptosis in prostate cancer Cancer Research. 72: 3052-3052. DOI: 10.1158/1538-7445.Am2012-3052 |
0.749 |
|
| 2011 |
Ringer L, Sirajuddin P, Heckler M, Ghosh A, Suprynowicz F, Yenugonda VM, Brown ML, Toretsky JA, Uren A, Lee Y, MacDonald TJ, Rodriguez O, Glazer RI, Schlegel R, Albanese C. VMY-1-103 is a novel CDK inhibitor that disrupts chromosome organization and delays metaphase progression in medulloblastoma cells. Cancer Biology & Therapy. 12: 818-26. PMID 21885916 DOI: 10.4161/Cbt.12.9.17682 |
0.732 |
|
| 2010 |
Ringer L, Sirajuddin P, Yenugonda VM, Ghosh A, Divito K, Trabosh V, Patel Y, Brophy A, Grindrod S, Lisanti MP, Rosenthal D, Brown ML, Avantaggiati ML, Rodriguez O, Albanese C. VMY-1-103, a dansylated analog of purvalanol B, induces caspase-3-dependent apoptosis in LNCaP prostate cancer cells. Cancer Biology & Therapy. 10: 320-5. PMID 20574155 DOI: 10.4161/Cbt.10.4.12208 |
0.76 |
|
| 2010 |
Mi L, Sirajuddin P, Gan N, Wang X. A cautionary note on using N-acetylcysteine as an antagonist to assess isothiocyanate-induced reactive oxygen species-mediated apoptosis. Analytical Biochemistry. 405: 269-71. PMID 20541518 DOI: 10.1016/J.Ab.2010.06.015 |
0.325 |
|
| 2008 |
Ohta S, Lai EW, Morris JC, Pang AL, Watanabe M, Yazawa H, Zhang R, Green JE, Chan WY, Sirajuddin P, Taniguchi S, Powers JF, Tischler AS, Pacak K. Metastasis-associated gene expression profile of liver and subcutaneous lesions derived from mouse pheochromocytoma cells. Molecular Carcinogenesis. 47: 245-51. PMID 17957724 DOI: 10.1002/Mc.20388 |
0.639 |
|
| Show low-probability matches. |